FXH - ETF AI Analysis
Top Page
First Trust Health Care AlphaDEX Fund (FXH)
Rating:70Neutral
Price Target:―
Positive Factors
Recent Performance Momentum
The fund has shown strong recent gains over the past three months and year to date, indicating positive momentum in its strategy.
Broad Health Care Exposure
With many holdings spread across the health care sector, investors get diversified exposure within a single industry rather than relying on just a few companies.
Meaningful Size
The fund manages over a billion dollars in assets, suggesting it has enough scale and investor interest to support stable operations and trading.
Negative Factors
Single-Sector Concentration
Almost all of the ETF’s assets are in health care, so its performance is heavily tied to the fortunes of that one sector.
U.S.-Only Focus
The fund invests almost entirely in U.S. companies, offering little geographic diversification if the U.S. market or health care policy environment weakens.
Above-Average Expense Ratio
The ETF’s expense ratio is relatively high compared with many broad index funds, which means more of the returns are used to cover fees.
FXH vs. SPDR S&P 500 ETF (SPY)
AUM1.14B
RegionNorth America
Expense Ratio0.61%
Beta0.65
IssuerFirst Trust
Inception DateMay 08, 2007
Dividend Yield0.78%
Asset ClassEquity
Index TrackedStrataQuant Health Care Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume69,804
30 Day Avg. Volume58,950
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
152.61Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering74
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FXH Summary
FXH is an exchange-traded fund that focuses on the StrataQuant Health Care Index, giving you broad exposure to U.S. health care companies. It holds a mix of drug makers, medical device firms, and health care service providers, including well-known names like Pfizer and Cigna. Someone might invest in FXH to seek growth from long-term trends such as an aging population and ongoing medical innovation, while also gaining diversification within the health care sector. A key risk is that it is heavily concentrated in health care stocks, so its value can rise or fall sharply with changes in that industry.
How much will it cost me?The expense ratio for FXH is 0.62%, which means you’ll pay $6.20 per year for every $1,000 invested. This is higher than average because FXH is actively managed, using a specialized methodology to select and weight health care stocks for potential outperformance. Actively managed funds typically have higher costs due to the research and strategy involved.
What would affect this ETF?The FXH ETF, focused on the U.S. health care sector, could benefit from ongoing advancements in medical technology, increased demand for health care services due to aging populations, and innovation within its top holdings like biotechnology and pharmaceutical companies. However, it may face challenges from regulatory changes, pricing pressures in the health care industry, and broader economic conditions such as rising interest rates, which could impact growth-focused investments. Its strong exposure to North America provides stability but limits diversification outside the U.S.
FXH Top 10 Holdings
FXH is a pure U.S. health care play, and its story right now is all about innovative drug and diagnostics names pulling ahead while a few medical device giants lose steam. High-flying biotech and testing players like Natera, Guardant Health, and Regeneron are rising and giving the fund much of its spark, with Tenet Healthcare adding steady support from the services side. On the flip side, Boston Scientific and Globus Medical have been lagging, acting as a bit of ballast and tempering the otherwise upbeat tone across this concentrated health care lineup.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Natera | 2.79% | $31.84M | $49.78B | 103.66% | 73 Outperform | |
| Regeneron | 2.73% | $31.09M | $79.75B | 31.86% | 78 Outperform | |
| Universal Health | 2.68% | $30.50M | $10.68B | -3.30% | 74 Outperform | |
| Guardant Health | 2.56% | $29.17M | $23.47B | 205.82% | 61 Neutral | |
| Solventum Corporation | 2.53% | $28.81M | $15.12B | 17.70% | 73 Outperform | |
| Pfizer | 2.50% | $28.54M | $156.51B | 14.45% | 74 Outperform | |
| Zimmer Biomet Holdings | 2.47% | $28.13M | $18.46B | -3.14% | 73 Outperform | |
| Tenet Healthcare | 2.33% | $26.55M | $21.40B | 44.86% | 74 Outperform | |
| Halozyme | 2.27% | $25.89M | $12.31B | 43.04% | 73 Outperform | |
| Boston Scientific | 2.26% | $25.75M | $63.64B | -55.66% | 79 Outperform |
FXH Technical Analysis
Neutral
―
Price Trends
129.52
Positive
123.03
Positive
118.16
Positive
Market Momentum
0.14
Positive
47.96
Neutral
45.98
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FXH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 132.61, equal to the 50-day MA of 129.52, and equal to the 200-day MA of 118.16, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 47.96 is Neutral, neither overbought nor oversold. The STOCH value of 45.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FXH.
FXH Peer Comparison
Comparison Results
Performance Comparison
FXH
First Trust Health Care AlphaDEX Fund
130.77
22.74
21.05%
IYH
iShares U.S. Healthcare ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents